Ruxolitinib, an approved drug that targets TYK2, is a kinase inhibitor used to treat patients with myelofibrosis and polycythemia vera who have not responded to or are unable to tolerate the use of hydroxyurea, and to treat graft-versus-host disease when steroid treatments have failed. This evidence concerns the gene TYK2 and acquired polycythemia vera.